Erectile Dysfunction Drugs Market Size is valued at USD 2.58 billion in 2023 and is predicted to reach USD 4.60 billion by the year 2031 at a 7.7% CAGR during the forecast period for 2024-2031.
Erectile dysfunction refers to the condition where an individual is unable to gain or maintain an erection for a sufficient duration to engage in sexual activity. Sedentary lifestyle-related chronic disorders, including obesity, heart disease, diabetes, and hypertension, are major contributors to erectile dysfunction. Improvements in pharmacological research and development for erectile dysfunction treatments, a growing number of men suffering from the illness, and an aging population are all factors propelling the erectile dysfunction drugs market. An increase in R&D, a dramatic increase in the number of men with erectile dysfunction, and a general upsurge in the prevalence of chronic diseases, which include obesity, hypertension, and diabetes, are all factors propelling the industry ahead. In addition, the erectile dysfunction medications market is experiencing strong growth and demand, driven by several major factors, such as the increasing prevalence of lifestyle disorders and the widespread adoption of sedentary lifestyles.
However, the market expansion is impeded by stringent regulatory standards regarding the safety and health of the erectile dysfunction drugs market. Additionally, the prevalence of numerous side effects linked to this medication poses a risk to its growth. Furthermore, low patient adherence and the presence of cheaper counterfeit drugs are anticipated to decelerate the market for erectile dysfunction drugs. Global healthcare systems are under strain due to the COVID-19 epidemic. During a pandemic, the number of sterilization treatments performed by biotechnology and pharmaceutical businesses increases due to increased research and development activities and medicine manufacture. Because of this, the chemicals market is expected to experience expansion.
The erectile dysfunction drugs market is segmented based on drug, mode of administration, and distribution channel. The drug segment is categorized into avanafil (Stendra), muse suppository (Alprostadil), sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra, Staxyn). The mode of administration segment includes injections, oral, and topical. The distribution channel segment includes hospital pharmacies, online pharmacies, and retail pharmacies.
Retail pharmacists in the erectile dysfunction drugs market are expected to witness a significant global market share in 2023. They dispense pharmaceuticals and medical supplies to both the general public and other healthcare professionals, as well as a wide variety of personal care items, art supplies, photography equipment, and pet supplies.
The oral sector predominantly utilizes erectile dysfunction pharmaceuticals due to their exceptional efficacy and safety profile, making them the preferred choice, particularly in different countries such as the US, Germany, the UK, China, and India.
In the near future, the North American market for erectile dysfunction medications is projected to have the most significant market share in revenue. The plethora of research and development efforts focused on creating new pharmacological compounds, the growing need for medications to address erectile dysfunction, and the robust healthcare infrastructure in the region are the main factors contributing to this phenomenon. Furthermore, the Asia Pacific region is expected to experience noteworthy growth in the global market for erectile dysfunction pharmaceuticals. This may be attributed to the increasing population of elderly patients, the thriving generic pharmaceutical industry, and the prevalence of infections related to erectile dysfunction in this geographical area.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 2.58 Bn |
|
Revenue Forecast In 2031 |
USD 4.60 Bn |
|
Growth Rate CAGR |
CAGR of 7.7 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Drug, Mode Of Administration, And Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
|
Competitive Landscape |
Adamed Sp. z o.o., Bayer AG, Cipla Limited, Dr. Reddys Laboratories Ltd., Eli Lilly and Company, Endo International PLC, Futura Medical PLC, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Novartis International AG, Pfizer Inc., S.K. Chemicals Co. Ltd., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Vivus, Inc. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Erectile Dysfunction Drugs Market Snapshot
Chapter 4. Global Erectile Dysfunction Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Drug Estimates & Trend Analysis
5.1. by Drug & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Drug:
5.2.1. Avanafil (Stendra)
5.2.2. Muse Suppository (Alprostadil)
5.2.3. Sildenafil (Viagra)
5.2.4. Tadalafil (Cialis)
5.2.5. Vardenafil (Levitra, Staxyn)
Chapter 6. Market Segmentation 2: by Mode of Administration Estimates & Trend Analysis
6.1. by Mode of Administration & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Mode of Administration:
6.2.1. Injections
6.2.2. Oral
6.2.3. Topical
Chapter 7. Market Segmentation 3: by Distribution Channel Estimates & Trend Analysis
7.1. by Distribution Channel & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Distribution Channel:
7.2.1. Hospital Pharmacies
7.2.2. Online Pharmacies
7.2.3. Retail Pharmacies
Chapter 8. Erectile Dysfunction Drugs Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2019-2031
8.1.2. North America Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Mode of Administration, 2019-2031
8.1.3. North America Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
8.1.4. North America Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.2. Europe
8.2.1. Europe Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2019-2031
8.2.2. Europe Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Mode of Administration, 2019-2031
8.2.3. Europe Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
8.2.4. Europe Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2019-2031
8.3.2. Asia Pacific Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Mode of Administration, 2019-2031
8.3.3. Asia-Pacific Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
8.3.4. Asia Pacific Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.4. Latin America
8.4.1. Latin America Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2019-2031
8.4.2. Latin America Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Mode of Administration, 2019-2031
8.4.3. Latin America Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
8.4.4. Latin America Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2019-2031
8.5.2. Middle East & Africa Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Mode of Administration, 2019-2031
8.5.3. Middle East & Africa Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
8.5.4. Middle East & Africa Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Adamed Sp. z o.o.
9.2.2. Bayer AG
9.2.3. Cipla Limited
9.2.4. Dr. Reddys Laboratories Ltd.
9.2.5. Eli Lilly and Company
9.2.6. Endo International PLC
9.2.7. Futura Medical PLC
9.2.8. GlaxoSmithKline PLC
9.2.9. Johnson & Johnson Services Inc.
9.2.10. Novartis International AG
9.2.11. Pfizer Inc.
9.2.12. S.K. Chemicals Co. Ltd.
9.2.13. Sanofi S.A.
9.2.14. Sun Pharmaceutical Industries Ltd.
9.2.15. Teva Pharmaceutical Industries Ltd.
9.2.16. Vivus, Inc.
9.2.17. Other Prominent Players
Erectile Dysfunction Drugs Market By Drug-
Erectile Dysfunction Drugs Market By Mode of Administration-
Erectile Dysfunction Drugs Market By Distribution Channel-
Erectile Dysfunction Drugs Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
